Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Leuk Res Rep ; 15: 100243, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34040959

RESUMO

Major disease complications for patients with essential thrombocythemia (ET) include thrombosis and fibrotic or leukemic transformation. Calreticulin (CALR) mutation type 1 frequencies in ET are estimated between 7% and 11% and ET patients carrying CALR type 1 mutation are associated with lower risk of thrombosis but higher risk of myelofibrosis transformation compared to ET patients with JAK2 mutation. Leukemic transformation rates at 20 years are estimated at less than 5% for ET and risk factors for leukemic transformation are advanced age, thrombosis history, leukocytosis, and anemia. Amongst the subtypes of blast phase myeloproliferative neoplasms, acute promyelocytic leukemia is extremely rare. Herein, we present a case of a promyelocytic blast crisis of post-ET myelofibrosis with associated life-threatening splanchnic vein thrombosis. This case suggests that inflammation plays a key role in thrombotic events and fibrotic/leukemic transformation in ET patients, regardless the molecular landscape.

2.
Cell Prolif ; 45(1): 66-75, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22168227

RESUMO

OBJECTIVES: We have investigated foetal mesenchymal stem cells (MSCs) obtained from first-trimester chorionic villi (CV) and second-trimester amniotic fluid (AF), comparing them to adult bone marrow-derived MSCs. MATERIALS AND METHODS: We report on cell population growth in human allogeneic serum (HS) and platelet lysate (PL), immunophenotype, cytokine expression profile and immunoregulatory activity, of these foetal MSCs on stimulated peripheral blood mononuclear and lymphocyte subpopulations. RESULTS: Chorionic villi cells grow rapidly in HS, with 20 populations doublings (PDs) after 59 days (six passages), and also in animal serum, with 27 PDs after 65 days (seven passages). PL allowed for expansion in 60% of the samples tested, although it was lower than in HS. HS supported an average of 40 PDs of expansion in 20% of AF cells after 90 days, whereas animal serum supported 28.5 PDs in 66 days. CV and AF cells inhibited proliferation of stimulated T lymphocytes, suppressing population growth of both CD4+ and CD8+ T subpopulations and sometimes also, CD19+ cells. CONCLUSIONS: Our results indicate that CV would be an optimal source of MSCs with high expansion potential in a HS propagation system and immunoregulatory capacity of T and B lymphocytes. More than 90% of CV samples achieved large-scale expansion in HS, which is encouraging for potential clinical applications of these cells.


Assuntos
Vilosidades Coriônicas/embriologia , Meios de Cultura , Células-Tronco Mesenquimais/citologia , Adolescente , Adulto , Líquido Amniótico/citologia , Animais , Plaquetas , Células da Medula Óssea/citologia , Células da Medula Óssea/imunologia , Diferenciação Celular , Proliferação de Células , Citocinas/metabolismo , Feminino , Perfilação da Expressão Gênica , Humanos , Imunofenotipagem , Células-Tronco Mesenquimais/imunologia , Pessoa de Meia-Idade , Células-Tronco Multipotentes/citologia , Células-Tronco Multipotentes/imunologia , Gravidez , Especificidade da Espécie , Adulto Jovem
3.
Cytotherapy ; 11(2): 153-62, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19301169

RESUMO

BACKGROUND: Mesenchymal stromal cells (MSC) are promising candidates for cell therapy and tissue engineering and may be used to treat acute graft-versus-host disease (GvHD). However, major obstacles for their clinical use are the required cell dose and the biosafety and potential immunogenicity of fetal bovine serum (FBS), which is a crucial supplement of all media currently used for the culture of MSC. METHODS: In this study MSC were successfully expanded after selection of CD271 cells from human bone marrow (BM) mononuclear cells in medium supplemented with 10% pooled allogeneic human serum. RESULTS: We isolated MSC from 10 healthy donor BM by plastic adherence and immunomagnetic selection of the CD271(+) fraction and expanded MSC in medium supplemented with pooled human allogeneic serum and animal serum. We isolated a homogeneous multipotent population by CD271(+) selection with a proliferation rate that was higher than MSC isolated by plastic adherence, 6.8+/-1.57 compared with 2.07+/-1.40 logs. Similar to cells generated in animal serum medium, MSC from allogeneic human serum were positive for mesenchymal markers and negative for hematopoietic markers; moreover they expressed embryonic stem cell genes. A normal karyotype and differentiation capacity into adipogenic, osteogenic and chondrogenic lineages and neurosphere-like structures were preserved throughout long-term culture. DISCUSSION: Expansion of MSC is both feasible and large with a CD271-selected population in medium supplemented with 10% pooled allogeneic human serum, without loss of multipotent differentiation capacity or karyotype alterations.


Assuntos
Células da Medula Óssea/citologia , Proliferação de Células , Células-Tronco Mesenquimais/citologia , Proteínas do Tecido Nervoso/biossíntese , Receptores de Fator de Crescimento Neural/biossíntese , Células Estromais/citologia , Animais , Antígenos de Diferenciação/genética , Antígenos de Diferenciação/metabolismo , Bovinos , Adesão Celular , Diferenciação Celular , Linhagem da Célula , Separação Celular , Células Cultivadas , Meios de Cultura , Citometria de Fluxo , Histocompatibilidade , Humanos , Células-Tronco Mesenquimais/metabolismo , Soro , Células Estromais/metabolismo
4.
Cytotherapy ; 10(7): 690-7, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18985476

RESUMO

BACKGROUND: Mesenchymal stromal cells (MSC) have been identified in a variety of fetal and adult tissues, including bone marrow (BM), fetal blood and liver. We report on the isolation, expansion and differentiation in vitro of MSC-like cells from chorionic villi (CV). METHODS: We evaluated 10 samples of CV collected at the first trimester (gestational age 11-13 weeks). We only used cells taken from back-up culture after a successful karyotype analysis. CV cells were characterized by morphologic, immunophenotypic and molecular analysis. The differentiation ability of mesenchymal and neural lineages was detected using specific culture conditions. Cell expansion was assessed after plating cells at different densities in different media, supplemented with animal and human serum. RESULTS: CV cells showed a homogeneous population of spindle-shaped cells after the first passage. Cells expressed CD90, CD105, CD73, CD44, CD29 and CD13 but not CD45, CD14, CD34 and CD117. They expressed Oct-4, Rex-1, GATA-4 and nestin, which characterize the undifferentiated stem cell state. They differentiated into osteocytes, adipocytes, chondrocytes and neuronal cells. Cell expansion was greater than that of adult BM-derived MSC, 9 logs with fetal bovine serum and 6 logs with human serum. Despite their high proliferative capacity, we did not observe any karyotypic abnormalities after culture. DISCUSSION: Our study shows that CV cells have better potential for expansion than adult stem cells. They can proliferate in a medium with human allogeneic serum and can differentiate into mesenchymal and neural lineages. CV cells may be an excellent cell source for therapeutic applications.


Assuntos
Diferenciação Celular , Vilosidades Coriônicas/fisiologia , Células-Tronco Mesenquimais/citologia , Primeiro Trimestre da Gravidez , Biomarcadores/análise , Proliferação de Células , Células Cultivadas , Feminino , Perfilação da Expressão Gênica , Humanos , Imunofenotipagem , Cariotipagem , Células-Tronco Mesenquimais/fisiologia , Gravidez
6.
Leukemia ; 20(2): 329-35, 2006 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-16341047

RESUMO

The engraftment ability of mesenchymal cells was investigated in 26 patients receiving allogeneic transplantation from HLA-identical siblings with reduced-intensity conditioning (RIC). The stem cell source was bone marrow (BM) in eight patients and G-CSF-mobilized peripheral blood hematopoietic cells in 18 cases. A total of 32 patients engrafted very quickly and the chimerism evaluation (both on myeloid and on lymphoid subsets) showed that they were full donor by day 60. At the time of the study they were in complete hematological remission and displayed a full donor hematopoiesis. Two patients showed early disease progression while one did not engraft. Forty-eight out-marrow samples harvested from the 26 patients generated a marrow stromal layer adequate for the chimerism evaluation. Monocyte-macrophage contamination of marrow stromal layers was always reduced below 2% by repeated trypsinizations and treatment with the leucyl-leucine (leu-leu) methyl ester. The chimerism evaluation was performed by PCR analysis of STRs microsatellites and the amelogenin locus, by using capillary electrophoresis (CE) and by FISH analysis in case of the sex mismatch. In eight patients, a partial donor origin of stromal cells was shown (7-86% cells of donor). The source of hematopoietic cells was BM in three patients and mobilized peripheral blood in the other five.


Assuntos
Sobrevivência de Enxerto/imunologia , Transplante de Células-Tronco Hematopoéticas , Células-Tronco Mesenquimais/imunologia , Condicionamento Pré-Transplante/métodos , Adulto , Idoso , Células Cultivadas , Quimerismo , Progressão da Doença , Feminino , Humanos , Técnicas In Vitro , Masculino , Pessoa de Meia-Idade , Transplante Homólogo
7.
Eur J Clin Microbiol Infect Dis ; 13(9): 756-60, 1994 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-7843181

RESUMO

In a study to determine the value of antigen and antibody detection in the serological diagnosis of invasive aspergillosis in patients with hematological malignancies, 436 sequential serum samples from 79 neutropenic patients were tested. Circulating galactomannan antigen was detected with a latex agglutination method (Pastorex Aspergillus) and antibody to Aspergillus fumigatus with an immunodiffusion test on agar gel. Among the 79 patients 18 cases of invasive aspergillosis were detected (4 proven, 6 highly probable, 3 probable, 5 suspected). Antigen was detected in 7 of these 18 patients. The sensitivity of the antigen test was 38.8% and the specificity 95%. The antibody test showed 55.5% sensitivity and 100% specificity. In this study the antigen test was less sensitive than previously reported but highly specific and might serve as a supplementary diagnostic test.


Assuntos
Anticorpos Antifúngicos/sangue , Antígenos de Fungos/sangue , Aspergilose/diagnóstico , Aspergillus/imunologia , Fungemia/diagnóstico , Doenças Hematológicas/complicações , Neutropenia/complicações , Aspergilose/sangue , Aspergilose/complicações , Feminino , Fungemia/sangue , Fungemia/complicações , Doenças Hematológicas/sangue , Humanos , Masculino , Neutropenia/sangue , Sensibilidade e Especificidade , Testes Sorológicos/métodos
9.
Boll Ist Sieroter Milan ; 70(1-2): 527-9, 1991.
Artigo em Inglês | MEDLINE | ID: mdl-1670057

RESUMO

We present a case of young male treated for a recurrence of Acute Non Lymphoid Leukemia who presented a colonization by C. krusei during prophylaxis with Fluconazole. The fever episode, which he developed while neutropenic, was resolved with the addition of Amphotericin B after the failure of empiric antibiotic therapy. No isolation was performed in blood cultures. A second cycle of antiblastic chemotherapy was needed because of the resistance shown to the first. Despite the prophylaxis with Fluconazole a stream of C. krusei grew in all the blood cultures collected while febrile. Amphotericin B administered did not control the fungemia. We discuss the resistance of C. krusei to Fluconazole.


Assuntos
Candida/efeitos dos fármacos , Candidíase/microbiologia , Fluconazol/farmacologia , Fungemia/microbiologia , Adulto , Anfotericina B/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Candidíase/tratamento farmacológico , Candidíase/etiologia , Candidíase/prevenção & controle , Candidíase Bucal/tratamento farmacológico , Candidíase Bucal/etiologia , Candidíase Bucal/microbiologia , Citarabina/administração & dosagem , Resistência Microbiana a Medicamentos , Quimioterapia Combinada/uso terapêutico , Evolução Fatal , Fluconazol/uso terapêutico , Flucitosina/uso terapêutico , Fungemia/tratamento farmacológico , Fungemia/etiologia , Humanos , Leucemia Mieloide Aguda/complicações , Leucemia Mieloide Aguda/tratamento farmacológico , Masculino , Mitoxantrona/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA